Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study
Recommended Citation
Alsakarneh S, Al Ta'ani O, Aburumman R, Mikhail I, Hashash JG, and Farraye FA. Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study. Aliment Pharmacol Ther 2025;62(1):72-76.
Document Type
Article
Publication Date
7-1-2025
Publication Title
Alimentary pharmacology & therapeutics
Abstract
IL-17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL-17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL-17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85-3.39). IL-17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.
Medical Subject Headings
Humans; Female; Male; Arthritis, Psoriatic; Interleukin-17; Inflammatory Bowel Diseases; Psoriasis; Middle Aged; Adult; Thalidomide; Anti-Inflammatory Agents, Non-Steroidal; Risk Factors; Aged; Antibodies, Monoclonal, Humanized
PubMed ID
40192577
ePublication
ePub ahead of print
Volume
62
Issue
1
First Page
72
Last Page
76
